APRE — Aprea Therapeutics, Inc.
Aprea Therapeutics, Inc. is a biopharmaceutical company in its clinical development stage, dedicated to discovering and marketing innovative cancer treatments. Their therapeutic approach centers on modulating DNA damage response pathways. The company's primary drug candidate, ATRN-119, is an oral ATR inhibitor currently undergoing Phase 1/2a clinical trials for patients with advanced solid tumors. Beyond this lead compound, Aprea's developmental pipeline includes ATRN-Backup, which is also an ATR inhibitor; ATRN-W1051, being explored for its anti-tumor effects; and ATRN-DDRi. Aprea Therapeutics, Inc. is headquartered in Boston, Massachusetts.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ Global Select
- Employees: 8
- Website: https://www.aprea.com
Latest SEC filings for APRE
- 8-K — 2026-08-28
- SCHEDULE 13G/A — 2026-08-13
- 8-K — 2026-08-12
- 10-Q — 2026-08-12
- 8-K — 2026-07-23
- 8-K — 2026-06-17
- 8-K — 2026-05-13
- 10-Q — 2026-05-13
- ARS — 2026-04-30
- EFFECT — 2026-04-30
Latest APRE news
- — Aprea Therapeutics to Present at October Conferences (globenewswire.com)
Educational tool only — not investment advice.